ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1322

Prevalence and Associated Factors of Sleep Disorders in Patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)

Marco Garrido-Cumbrera1, Victoria Navarro-Compán2, Laura Christen3, Christine Bundy4, Raj Mahapatra5, Souzi Makri6, Carlos-Jesus Delgado-Domínguez7, José Correa-Fernández8 and Denis Poddubnyy9, 1Health & Territory Research (HTR), Universidad de Sevilla / Spanish Federation of Spondyloarthritis Associations, Sevilla, Spain, 2Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 3Novartis Pharma AG, Basel, Switzerland, 4Cardiff University, Cardiff, United Kingdom, 5Axial Spondyloarthritis International Federation, London, United Kingdom, 6Cyprus League Against Rheumatism, Nicosia, Cyprus, 7Health & Territory Research, Seville, Spain, 8Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain, 9Charité – Universitätsmedizin Berlin, Berlin, Germany

Meeting: ACR Convergence 2020

Keywords: Patient reported outcomes, sleep, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Sleep is an essential health aspect that is often impacted in patients with axial spondyloarthritis (axSpA). This analysis aims to assess the prevalence and associated factors of sleep disorders in a large sample of European axSpA patients.

Methods: Data were analyzed from 2,846 unselected patients with self-reported clinician-given diagnosis of axSpA of the European Map of Axial Spondyloarthritis (EMAS) through an online survey (2017-2018) across 13 European countries. Socio-demographic data; BASDAI [0-10] scores; engagement in physical activity; axSpA influence on work choice (assessed with yes/no question “Was your current or past work choice in any way determined by axSpA?”),; risk of psychological distress (12-item General Health Questionnaire [GHQ-12; 0-12]); functional limitation [0-54] and self-reported anxiety and depression were evaluated. Presence of sleep disorders was assessed by the question: “Please indicate whether you have been diagnosed with any of the following: sleep disorders”. A Mann-Whitney test was used to compare the means of numerical variables between dichotomous variables, the Chi-Square test was used to compare the distribution between the categorical variables. Simple and multivariable logistic regression models were used to identify associations between sleep disorders and disease characteristics, mental health and work-related variables.

Results: Age of respondents was 43.9 years; 61.3% were female; 48.1% had a university degree; 67.9% were married and 71.3% were HLA-B27 positive. The prevalence of sleep disorders was 39.0%. In the bivariate analysis, presence of sleep disorders was associated with female gender (68.3% vs. 31.7%; p< 0.001); overweight/obese (56.5% vs. 49.8%; p< 0.001); increased BASDAI scores (6.1±1.8 vs. 5.0±2.1; p< 0.001); fatigue (7.0±2.0 vs. 5.8±2.4; p< 0.001); morning stiffness (5.8±2.4 vs. 4.8±2.4; p< 0.001), work impact (56.5% vs. 38.2%; p< 0.001); anxiety (56.8% vs. 12.5%; p< 0.001); depression (51.8% vs. 10.1%; p< 0.001) and higher GHQ-12 scores (6.4±4.0 vs. 3.9±3.9; p< 0.001) [Table 1]. However, factors that remained independently associated with sleep disorders in the multivariable analysis were anxiety (OR=3.8 p< 0.001) and depression (OR=3.1 p< 0.001) and female gender (OR=1.4; p=0.002) [Table 2]. According to employment status, the greatest prevalence of sleep disorders was concentrated in those on permanent sick leave (52.3%) and temporary sick leave (50.2%). [Table 3].

Conclusion: Sleep disorders were highly prevalent among axSpA European patients and strongly associated with female gender and reporting worse mental health, and spinal stiffness. Patients on permanent and temporary sick leave were more likely to report sleep disorders. The strong association between sleep disorders with both anxiety and depression should encourage rheumatologists to screen their patients with sleep disturbance in case they require additional specialist support.

Table 1. Sociodemographic characteristics and patient-reported outcomes by presence of sleep disorders (N = 2713, unless otherwise specified)

Table 2. Regression analysis to predict presence of sleep disorders (N = 2191)

Table 3. Presence of sleep disorders according to employment status categories (N = 2,580)


Disclosure: M. Garrido-Cumbrera, None; V. Navarro-Compán, Novartis Pharma, 1, 5, 8, AbbVie Inc., 5, 8, Eli Lilly and Company, 5, 8, Pfizer Inc., 5, UCB, 5, 8; L. Christen, Novartis Pharma AG, 3; C. Bundy, Abbvie, 8, Celgene, 8, Janssen, 8, Lilly, 8, Novartis, 8, Pfizer, 8; R. Mahapatra, None; S. Makri, None; C. Delgado-Domínguez, None; J. Correa-Fernández, None; D. Poddubnyy, Eli Lilly and Company, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, BioCad, 5, Gilead, 5, GSK, 5, UCB, 5, 8, BMS, 8.

To cite this abstract in AMA style:

Garrido-Cumbrera M, Navarro-Compán V, Christen L, Bundy C, Mahapatra R, Makri S, Delgado-Domínguez C, Correa-Fernández J, Poddubnyy D. Prevalence and Associated Factors of Sleep Disorders in Patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-associated-factors-of-sleep-disorders-in-patients-with-axial-spondyloarthritis-results-from-the-european-map-of-axial-spondyloarthritis-emas/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-associated-factors-of-sleep-disorders-in-patients-with-axial-spondyloarthritis-results-from-the-european-map-of-axial-spondyloarthritis-emas/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology